Research programme: herpes simplex virus type 2 vaccines - Vaccibody
Latest Information Update: 15 Aug 2016
At a glance
- Originator Vaccibody
- Class DNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus type 2 infections
Most Recent Events
- 05 Jul 2016 Preclinical trials in Herpes simplex virus type-2 infections (Prevention) in Norway (Parenteral, injection)